Pharmacoeconomics

Introduction to Pharmacoeconomics; Decision Modeling Techniques; Multiple Criteria Decision Analysis (MCDA); Cost of Illness; Markov Modeling in Decision Analysis; Novel Modeling Methods (DICE); Retrospective Database Analysis; What is Cost-Minimization Analysis?; Cost-Effectiveness Analysis; Budget Impact Analysis; Cost-Utility Analysis: A Case Study of a Quadrivalent Human Papillomavirus Vaccine; Some Problems/Assumptions in Pharmacoeconomic Analysis; Patient-Reported Outcome Measures; Sensitivity Analysis; Use of Pharmacoeconomics in Drug Reimbursement in Australia, Canada, and the United Kingdom: What Can We Learn from International Experience?; Implementation of Value Frameworks in Reimbursement Decisions in the US and Beyond, NICE (UK) and PBAC (Australia; Pharmacoeconomics in Disease Management: Practical Applications and Persistent Challenges; Computer Aided Decision Making from Drug Discovery to Pharmacoeconomics; Speculations on the Future Challenges and Value of Pharmacoeconomics.

Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.

• Farmacologia
• Tecnologia farmacêutica
• Medicina: temas gerais
• Pesquisa médica

Antenatal HIV Testing;Net Budget Impact;pharmacoeconomics;Tufts Medical Center;cost-effectiveness analysis;Health Technology Assessment;decision modeling;HTA;cost-utlity analysis;ICERs;Pharmacoeconomics theory into real world practices;Pharmacoeconomic Analyses;Health Outcomes Research (OR);Markov Cohort Model;Health technology assessment (HTA);Health Technology Assessment Bodies;NICE (UK) and PBAC (Australia);Human Papillomavirus Vaccine;Cost-Minimization Analysis;Cervical Cancer;Global aging;COI Study;medication shortages;Probabilistic Sensitivity Analyses;numerous stakeholders;CUA;pharmacoeconomic models;HTA Agency;pharmaceutical industry;Cost Effectiveness Ratio;patient segmentation;Discrete Event Simulation;Pe Model;Cost Effectiveness Threshold;Budget Impact;PD;Pe Guideline;Dm Program;Data Sets;NI Trial